Half of them are exclusively focused on RCC and two-thirds are based on conventional chemotherapeutic drugs, which are able to target rapidly proliferating cells in both normal and cancer tissues: 10 were focused on the role of TKI, mainly sunitinib, sorafenib and pazopanib, and another 5 aimed at blocking VEGF with bevacizumab or its Fab fragment ranibizumab (Table 1). The gene discussed is VEGFA; the disease is cancer.